Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06707142 · ClinicalTrials.gov registry record · Phase 1

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

A Phase 1 study of Healthy Adult Participants, sponsored by Gates Medical Research Institute.

Recruiting
Registry status
Phase 1
Development phase
124
Enrollment target
1
Study location

NCT06707142 is a Phase 1 study of Healthy Adult Participants that is actively recruiting participants, run by Gates Medical Research Institute. The registered enrollment target is 124 participants, above the 49-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06707142, a Phase 1 study of Healthy Adult Participants, is actively recruiting participants, sponsored by Gates Medical Research Institute.

RECRUITING
Registry status
Phase 1
Development phase
124 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (MAD) cohorts and tablet formulation evaluation (Part 2, Cohort 4).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG TBD11

Study Locations (1)

Nebraska

  • Celerion - Lincoln

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2024-12-05
Est. Completion 2026-02
Phase Phase 1

Sponsor

Gates Medical Research Institute

6 total trials

What the Registry Record Tells You About NCT06707142

The ClinicalTrials.gov registry entry for NCT06707142 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 49-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (153% higher). The listed sponsor is Gates Medical Research Institute, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06707142 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT06707142 about?

NCT06707142 is a clinical study titled "A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11". This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (M...

What is the current status of trial NCT06707142?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2024-12-05. Estimated completion is 2026-02.

What conditions does trial NCT06707142 study?

This clinical trial studies the following conditions: Healthy Adult Participants.

What interventions are being tested in trial NCT06707142?

The interventions under investigation include: Placebo (DRUG), TBD11 (DRUG).

Who is sponsoring clinical trial NCT06707142?

This trial is sponsored by Gates Medical Research Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06707142 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.